Acute Lymphoblastic Leukaemias (ALL) Recruiting Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Acute Lymphoblastic Leukemia(ALL) / Acute Leukaemia, Lymphoblastic / Leukemia, Acute Lymphoblastic / Acute Lymphoblastic Leukemias / Acute Lymphoblastic Leukemia / Acute Lymphoblastic Leukaemia / Lymphoblastic Leukemia, Acute / Acute Lymphoblastic Leukemia (ALL) / Acute Leukemia, Lymphoblastic / Leukaemia, Lymphoblastic, Acute / Leukemia, Lymphoblastic, Acute / Acute lymphoblastic leukemia with failed remission / Leukemia lymphoblastic acute / Lymphoid leukaemia, acute / Acute lymphoid leukaemia / Lymphoid leukemia, acute / Acute lymphoid leukemia / ALL / Leukaemia lymphoblastic acute / Acute lymphocytic leukemia / Acute lymphatic leukaemia / Leukaemias acute lymphocytic / Acute lymphatic leukemia / Acute lymphocytic leukaemia

IndicationStatusPhase
DBCOND0073466 (Acute Lymphoblastic Leukaemias (ALL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03821610A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Treatment